Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT06308588 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Chromosome-Positive
Acute Lymphoblastic Leukemia

Interventions

DRUG: Blinatumomab
DRUG: Asciminib

Sponsor

M.D. Anderson Cancer Center

Collaborators

Novartis Pharmaceuticals